{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:57:47Z","timestamp":1791334667829,"version":"4.3.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","award":["PHRCI-19-013"],"award-info":[{"award-number":["PHRCI-19-013"]}],"id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015086","name":"AOP Orphan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Postoperative atrial fibrillation (PoAF) after cardiac surgery has a high incidence of 30%, but its management is controversial. Two strategies are recommended without evidence of a superiority of one against the other: rate control with beta-blocker or rhythm control with amiodarone. Landiolol is a new-generation beta-blocker with fast onset and short half-life. One retrospective, single-center study compared landiolol to amiodarone for PoAF after cardiac surgery with a better hemodynamic stability and a higher rate of reduction to sinus rhythm with landiolol, justifying the need for a multicenter randomized controlled trial. Our aim is to compare landiolol to amiodarone in the setting of PoAF after cardiac surgery with the hypothesis of a higher rate of reduction to sinus rhythm with landiolol during the 48\u00a0h after the first episode of POAF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The FAAC trial is a multicenter single-blind two parallel-arm randomized study, which planned to include 350 patients with a first episode of PoAF following cardiac surgery. The duration of the study is 2\u00a0years. The patients are randomized in two arms: a landiolol group and an amiodarone group.<\/jats:p>\n                <jats:p>Randomization (Ennov Clinical\u00ae) is performed by the anesthesiologist in charge of the patient if PoAF is persistent for at least 30\u00a0min after correction of hypovolemia, dyskalemia, and absence of pericardial effusion on a transthoracic echocardiography done at bedside.<\/jats:p>\n                <jats:p>Our hypothesis is an increase of the percentage of patients in sinus rhythm from 70 to 85% with landiolol in less than 48\u00a0h after onset of PoAF (alpha risk\u2009=\u20095%, power\u2009=\u200990%, bilateral test).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The FAAC trial was approved by the Ethics Committee of EST III with approval number 19.05.08. The FAAC trial is the first randomized controlled trial comparing landiolol to amiodarone for PoAF after cardiac surgery. In case of higher rate of reduction with landiolol, this beta-blocker could be the drug of choice used in this context as to reduce the need for anticoagulant therapy and reduce the risk of complications of anticoagulant therapy for patients with a first episode of postoperative atrial fibrillation after cardiac surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov NCT04223739. Registered on January 10, 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07353-6","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T23:04:37Z","timestamp":1684969477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of landiolol and amiodarone for the treatment of new-onset atrial fibrillation after cardiac surgery (FAAC) trial: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Edouard","family":"Caspersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Gr\u00e9goire","family":"Guinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Rozec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Ferr\u00e9ol","family":"Oilleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Fellahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Lorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazine","family":"Mahjoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Besnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhamed Djahoum","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mongardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Hanouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs R.","family":"Briant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure Peyro Saint","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Tomadesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Parienti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Denisenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Olivier","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ARCOTHOVA Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"7353_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS). Eur Heart J. 2020;42:373\u201398.","journal-title":"Eur Heart J"},{"key":"7353_CR2","doi-asserted-by":"crossref","unstructured":"American College of Cardiology Foundation; American Heart Association; European Society of Cardiology; Heart Rhythm Society, Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF\/AHA\/ESC and 2011 ACCF\/AHA\/HRS recommendations): a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. Circulation. 2013;127:1916\u201326.","DOI":"10.1161\/CIR.0b013e318290826d"},{"key":"7353_CR3","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u20132962.","DOI":"10.5603\/KP.2016.0172"},{"key":"7353_CR4","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1056\/NEJMoa1602002","volume":"374","author":"AM Gillinov","year":"2016","unstructured":"Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016;374:1911\u201321.","journal-title":"N Engl J Med"},{"key":"7353_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMc1607939","volume":"375","author":"MO Fischer","year":"2016","unstructured":"Fischer MO, Fellahi JL, Lorne E. Rate control or rhythm control for atrial fibrillation after heart surgery. N Engl J Med. 2016;375:799.","journal-title":"N Engl J Med"},{"key":"7353_CR6","doi-asserted-by":"publisher","first-page":"A4","DOI":"10.1093\/eurheartj\/sux038","volume":"20","author":"JL Fellahi","year":"2018","unstructured":"Fellahi JL, Heringlake M, Knotzer J, Fornier W, Cazenave L, Guarracino F. Landiolol for managing atrial fibrillation in post-cardiac surgery. Eur Heart J Suppl. 2018;20:A4\u20139.","journal-title":"Eur Heart J Suppl"},{"key":"7353_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5761\/atcs.ed.13-00374","volume":"20","author":"A Sezai","year":"2014","unstructured":"Sezai A, Shiono M. The role of \u03b2-blockers in cardiac perioperative management. Ann Thorac Cardiovasc Surg. 2014;20:261\u20136.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"7353_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.jvca.2015.09.007","volume":"30","author":"SC Shibata","year":"2016","unstructured":"Shibata SC, Uchiyama A, Ohta N, Fujino Y. Efficacy and safety of landiolol compared to amiodarone for the management of postoperative atrial fibrillation in intensive care patients. J Cardiothorac Vasc Anesth. 2016;30:418\u201322.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"7353_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.accpm.2020.10.012","volume":"39","author":"E Toulouse","year":"2020","unstructured":"Toulouse E, Lafont B, Granier S, Mcgurk G, Bazin JE. French legal approach to patient consent in clinical research. Anesthe Crit Care Pain Med. 2020;39:883\u20135.","journal-title":"Anesthe Crit Care Pain Med"},{"key":"7353_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJG. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263\u201372.","journal-title":"Chest"},{"key":"7353_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"7353_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/europace\/eur208","volume":"14","author":"B Maesen","year":"2012","unstructured":"Maesen B, Nijs J, Maessen J, Allessie M, Schotten U. Post-operative atrial fibrillation: a maze of mechanisms. Europace. 2012;14:159\u201374.","journal-title":"Europace"},{"issue":"23","key":"7353_CR13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/europace\/euab095","volume":"8","author":"MJ Kawczynski","year":"2021","unstructured":"Kawczynski MJ, Gilbers M, Van De Walle S, Schalla S, Crijns HJ, Maessen JG, et al. Role of pre-operative transthoracic echocardiography in predicting post-operative atrial fibrillation after cardiac surgery: a systematic review of the literature and meta-analysis. Europace. 2021;8(23):1731\u201343.","journal-title":"Europace"},{"key":"7353_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1213\/ANE.0000000000003865","volume":"128","author":"B O'Brien","year":"2019","unstructured":"O\u2019Brien B, Burrage PS, Ngai JY, Prutkin JM, Huang CC, Xu X, et al. Society of cardiovascular anesthesiologists\/European association of cardiothoracic anaesthetists practice advisory for the management of perioperative atrial fibrillation in patients undergoing cardiac surgery. Anesth Analg. 2019;128:33\u201342.","journal-title":"Anesth Analg"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07353-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07353-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07353-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T23:04:47Z","timestamp":1684969487000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07353-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7353"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07353-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board (IRB) of the University Hospital of Caen (Comit\u00e9 de Protection des Personnes Nord-Ouest III, Avenue la C\u00f4te de Nacre, Niveau 03, Porte 03\u2013508, 14 033 Caen Cedex 9, France) approved the study for all co-investigators centers (Registration number ID RDB: 2019-A00763-54). The FAAC trial is conducted in accordance with the Declaration of Helsinki and the French laws and was registered on January 10, 2020, on the ClinicalTrials.gov website with trial identification number NCT04223739. Written informed consent will be obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Participants of the study signed an informed consent form. This form includes consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The funders had no involvement in the collection analysis and interpretation of data. The authors and investigators declare that they have no competing interests, except for JL Fellahi, JF Oilleau, E Besnier, P Gaudard, B Rozec, and N Mongardon receiving payment from AOP Orphan Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"353"}}